Journal of Gastroenterology and Hepatology

Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: A retrospective analysis

Corresponding Author

Isabelle Colle

Laboratoire d’Hémodynamique Splanchnique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale U-481,

Service d’Hépatologie and

Dr I Colle, Department of Hepato-Gastroenterologie, University Hospital of Ghent (UZ-Ghent), De Pintelaan 185, 9000 Ghent, Belgium. Email: [email protected]Search for more papers by this author

François Durand,

François Durand

Laboratoire d’Hémodynamique Splanchnique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale U-481,

Service d’Hépatologie and

Search for more papers by this author

Fabienne Pessione,

Fabienne Pessione

Unité de Traitement Ambulatoire de Maladie Alcoolique, Hôpital Beaujon, Clichy, France

Search for more papers by this author

Emmanuel Rassiat,

Emmanuel Rassiat

Laboratoire d’Hémodynamique Splanchnique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale U-481,

Service d’Hépatologie and

Search for more papers by this author

Jacques Bernuau,

Jacques Bernuau

Laboratoire d’Hémodynamique Splanchnique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale U-481,

Service d’Hépatologie and

Search for more papers by this author

Eric Barrière,

Eric Barrière

Laboratoire d’Hémodynamique Splanchnique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale U-481,

Service d’Hépatologie and

Search for more papers by this author

Didier Lebrec,

Didier Lebrec

Laboratoire d’Hémodynamique Splanchnique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale U-481,

Service d’Hépatologie and

Search for more papers by this author

Dominique-Charles Valla,

Dominique-Charles Valla

Laboratoire d’Hémodynamique Splanchnique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale U-481,

Service d’Hépatologie and

Search for more papers by this author

Richard Moreau,

Richard Moreau

Laboratoire d’Hémodynamique Splanchnique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale U-481,

Service d’Hépatologie and

Search for more papers by this author

Isabelle Colle,

Corresponding Author

Isabelle Colle

Laboratoire d’Hémodynamique Splanchnique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale U-481,

Service d’Hépatologie and

Dr I Colle, Department of Hepato-Gastroenterologie, University Hospital of Ghent (UZ-Ghent), De Pintelaan 185, 9000 Ghent, Belgium. Email: [email protected]Search for more papers by this author

François Durand,

François Durand

Laboratoire d’Hémodynamique Splanchnique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale U-481,

Service d’Hépatologie and

Search for more papers by this author

Fabienne Pessione,

Fabienne Pessione

Unité de Traitement Ambulatoire de Maladie Alcoolique, Hôpital Beaujon, Clichy, France

Search for more papers by this author

Emmanuel Rassiat,

Emmanuel Rassiat

Laboratoire d’Hémodynamique Splanchnique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale U-481,

Service d’Hépatologie and

Search for more papers by this author

Jacques Bernuau,

Jacques Bernuau

Laboratoire d’Hémodynamique Splanchnique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale U-481,

Service d’Hépatologie and

Search for more papers by this author

Eric Barrière,

Eric Barrière

Laboratoire d’Hémodynamique Splanchnique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale U-481,

Service d’Hépatologie and

Search for more papers by this author

Didier Lebrec,

Didier Lebrec

Laboratoire d’Hémodynamique Splanchnique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale U-481,

Service d’Hépatologie and

Search for more papers by this author

Dominique-Charles Valla,

Dominique-Charles Valla

Laboratoire d’Hémodynamique Splanchnique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale U-481,

Service d’Hépatologie and

Search for more papers by this author

Richard Moreau,

Richard Moreau

Laboratoire d’Hémodynamique Splanchnique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale U-481,

Service d’Hépatologie and

Search for more papers by this author

First published: 07 August 2002

https://doi.org/10.1046/j.1440-1746.2002.02816.x

Citations: 115

Share a link

Email
Wechat
Bluesky

Abstract

Abstract Background and Aim: Terlipressin has been proposed to treat renal failure in patients with type 1 hepatorenal syndrome (HRS). However, the predictive factors for improved renal function and survival are unknown in patients with type 1 HRS treated with terlipressin. The aim of the present retrospective study was to investigate the predictive factors and prognosis of patients with type 1 HRS treated with terlipressin.

Methods: The clinical charts of 18 consecutive patients with cirrhosis and type 1 HRS treated with terlipressin were studied. The predictive factors for improved renal function and survival were identified using univariate analyses.

Results: Improved renal function, indicated by a significant decrease in serum creatinine (61 ± 4%), occurred in 11 (60%) patients. The only predictive factor for improved renal function was a Child–Pugh's score ≤13 at the time of diagnosis of HRS (P = 0.02). Fifteen patients (83%) died at 45 days and the median survival was 24 days. Of the three patients who survived, two underwent successful orthotopic liver transplantation. Three predictive factors for survival were identified: absence of a precipitating factor for HRS (P = 0.012); improved renal function during terlipressin therapy (P = 0.05); and a dose of terlipressin ≥3 mg/day (P = 0.04).

Conclusions: In patients with type 1 HRS treated with terlipressin, patients with improved renal function had less severe cirrhosis (Child–Pugh >10 but ≤13) than patients without. The predictive factors for survival were the absence of a precipitating factor for HRS, the terlipressin-induced improvement in renal function and a dose of terlipressin of at least 3 mg/day. These findings suggest that a randomized controlled trial investigating the effect of terlipressin on survival in patients with type 1 HRS should be performed.

References

1 Laffi G, La Villa G, Gentilini P. Pathogenesis and management of the hepatorenal syndrome. Semin. Liver Dis. 1994; 14: 71–81.
10.1055/s-2007-1007299
PubMed Web of Science® Google Scholar
2 Arroyo V, Ginès P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164–76.
10.1002/hep.510230122
CAS PubMed Web of Science® Google Scholar
3 Bataller R, Ginès P, Guevara M, Arroyo V. Hepatorenal syndrome. Semin. Liver Dis. 1997; 17: 233–47.
10.1055/s-2007-1007201
CAS PubMed Web of Science® Google Scholar
4 Lenz K, Hortnagel H, Druml W et al.. Ornipressin in the treatment of functional renal failure in decompensated cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 1991; 101: 1060–7.
10.1016/0016-5085(91)90734-3
PubMed Web of Science® Google Scholar
5 Guevara M, Ginès P, Fernandez-Esparrach G et al.. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35–41.
10.1002/hep.510270107
CAS PubMed Web of Science® Google Scholar
6 Hadengue A, Gadano A, Moreau R. et al.. Beneficial effects of the two-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J. Hepatol. 1998; 29: 565–70.DOI: 10.1016/S0168-8278(98)80151-7
10.1016/S0168-8278(98)80151-7
CAS PubMed Web of Science® Google Scholar
7 Gülberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamin. Hepatology 1999; 30: 870–5.
10.1002/hep.510300430
CAS PubMed Web of Science® Google Scholar
8 Uriz J, Ginès P, Cardenas A et al.. Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. J. Hepatol. 2000; 33: 33–48.
10.1016/S0168-8278(00)80459-6
PubMed Web of Science® Google Scholar
9 Bonnard P, Bernard B, Halimi C et al.. Effect of terlipressin (Glypressine®) on hepatorenal syndrome (HRS) in cirrhotic patients: Results of a pilot study (Abstract). Gastroenterology 1998; 114: A1214.
10.1016/S0016-5085(98)84925-1
Web of Science® Google Scholar
10 Le Moine O, Mulkay JP, Bourgeois N, Adler M, Devière J. Longterm terlipressin administration improves renal function in cirrhotic patients with hepatorenal syndrome (HRS): A pilot study (Abstract). Gastroenterology 1999; 116: A1258–9.
Web of Science® Google Scholar
11 Mulkay JP, Louis H, Donckier V et al.. Longterm terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: A pilot study. Acta Gastroenterol. Belg. 2001; 64: 15–19.
CAS PubMed Web of Science® Google Scholar
12 Gines P, Ortega R, Uriz J et al.. Effects of terlipressin administration with and without albumin in hepatorenal syndrome. A phase II study. Hepatology 2001; 34 (Part 2): P186A.
Google Scholar
13 Ginès A, Escorsell A, Ginès P et al.. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229–36.
10.1016/0016-5085(93)90031-7
CAS PubMed Web of Science® Google Scholar
14 Moreau R, Durand F, Poynard T et al.. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. Gastroenterology 2002; 122: 923–30.
10.1053/gast.2002.32364
CAS PubMed Web of Science® Google Scholar
15 Guarner C, Soriano G. Spontaneous bacterial peritonitis. Semin. Liver Dis. 1997; 17: 203–16.
10.1055/s-2007-1007198
PubMed Web of Science® Google Scholar
16 Fevery J, Van Cutsem E, Nevens F, Van Steenbergen W, Verberckmoes R, De Groote J. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J. Hepatol. 1990; 11: 153–8.
10.1016/0168-8278(90)90106-2
PubMed Web of Science® Google Scholar
17 Angeli P, Volpin R, Gerunda G et al.. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690–7.
10.1002/hep.510290629
CAS PubMed Web of Science® Google Scholar
18 Holt S, Goodier D, Marley R et al.. Improvement in renal function in hepatorenal syndrome with N-acetylcycteine. Lancet 1999; 353: 294–5.
10.1016/S0140-6736(05)74933-3
CAS PubMed Web of Science® Google Scholar
19 Gadano A, Moreau R, Vachiery F et al.. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J. Hepatol. 1997; 26: 1229–34.DOI: 10.1016/S0168-8278(97)80456-4
10.1016/S0168-8278(97)80456-4
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume17, Issue8

August 2002

Pages 882-888

Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: A retrospective analysis

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: A retrospective analysis

Abstract

References

Citing Literature

References

Related

Information